New Noninvasive Methods Detect Lead Exposure Faster, Easier and More Accurately at POC
|
By LabMedica International staff writers Posted on 30 Oct 2024 |

Exposure to lead can negatively affect health in multiple ways, leading to damage in the brain and central nervous system, delays in development and growth, learning and behavioral issues, problems with hearing and speech, reproductive health complications, kidney damage, high blood pressure, anemia, and more. The standard method for measuring lead exposure is through a blood test, which only reflects exposure from the past 30 days. If this test is conducted outside that timeframe—especially in children—clinicians may not receive results that accurately represent chronic cumulative exposure in the body. Additionally, measuring bone lead levels is crucial because lead, which mimics calcium upon entering the body, disrupts pathways to the brain and accumulates in the bone. However, older technologies used to assess bone lead exposure have several limitations, including their size, the need for specialized knowledge, reliance on rare elements, and slow processing times. Now, researchers have developed noninvasive methods that can detect lead exposure levels in both bone and blood more quickly, easily, and sensitively at the point of care compared to traditional techniques.
The innovative, patent-pending technology developed by researchers at Purdue University (West Lafayette, IN, USA) utilizes portable X-ray fluorescence (XRF) analyzers to measure lead exposure in bone and blood. This new approach with portable XRFs addresses the limitations associated with traditional bone testing. The XRF analyzer employs a straightforward ‘point-and-shoot’ process, and results are available on the analyzer's tablet within minutes. Training an individual to operate this system takes only about 30 minutes, enabling them to perform measurements that can identify community-level lead exposure. The next step for the research team involves securing support from health leaders to incorporate this technology into national cohort studies and routine surveillance, which could help establish national standards for cumulative lead exposure.
Additionally, researchers have developed a method for detecting lead levels in dried blood spots, which is a significant improvement over the traditional approach that requires venous blood draws sent to a laboratory for analysis. The new technique allows for lead detection using dried blood spots, which can be collected much more easily with just a finger prick, requiring only a small amount of capillary blood. As long as more than 10 microliters of blood is present on the dried spot, the test can provide an accurate lead measurement. Similar to the bone test technology, this innovation enhances accessibility for underserved communities and rural populations and offers better sensitivity than existing tests. Both advancements have potential applications for health officials globally. The research on these methods has been published in the September 2024 issue of Current Environmental Health Reports and the March 2021 issue of Environmental Science & Technology.
“It can be difficult to assess their lead exposure levels because it’s hard to get them to a centralized clinic, unlike in an urban environment where people visit a clinic often. By using a portable XRF analyzer, health officials can travel to a community, conduct testing, quickly receive results and move on to the next community,” said Aaron Specht, assistant professor in the School of Health Sciences, who has developed both the technologies. “Our new method detects lead using dried blood spots, which are much easier to collect; they require just a finger prick and only a very small volume of capillary blood. As long as there’s more than 10 microliters of blood on that dried blood spot, we will have an accurate measurement of lead.”
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







